Re: Saudi Arabia: 3 cases, 2 deaths due to novel animal coronavirus
Partial genetic sequence information for scientists about the Novel Coronavirus 2012
Development of diagnostics for novel coronavirus - added 26 September 2012
•HPA has received a number of requests about molecular diagnostics and whether broadly reactive primers will pick up this virus. The pan-coronavirus primers described by Emery et al 2004 and Vijgen et al 2008 should both work.
•The World Health Organisation has convened relevant European laboratories to work collaboratively to produce clinically validated assays for real-time detection of the novel coronavirus.
•The patient clinical material that HPA has does not react with the specific detection assays which we have for OC23 [OC43? - alert], 229E, NL63 or SARS.
•The whole genome of the material that is described in ProMed post#501 is expected to be published by Professor Ron Fouchier, Rotterdam, in the next 24-48 hours. This sequence will be based on cultured virus which has been in Rotterdam since early July.
•The sequence data that HPA has from the London case is based on direct detection in clinical material obtained at the weekend. The HPA does not yet have a virus isolate, although obviously clinical material is already in tissue culture in an attempt to make isolates from the London case.
•HPA welcomes offers of reagents or information from scientists working in this area which may be useful in this situation.
References:
Emery et al. Real-time reverse transcription-polymerase chain reaction assay for SARS-associated coronavirus. Emerg Infect Dis. 2004 Feb;10(2):311-6.
Vijgen et al. A pancoronavirus RT-PCR assay for detection of all known coronaviruses. Methods Mol Biol. 2008;454:3-12.
Partial genetic sequence information for scientists about the Novel Coronavirus 2012
Development of diagnostics for novel coronavirus - added 26 September 2012
•HPA has received a number of requests about molecular diagnostics and whether broadly reactive primers will pick up this virus. The pan-coronavirus primers described by Emery et al 2004 and Vijgen et al 2008 should both work.
•The World Health Organisation has convened relevant European laboratories to work collaboratively to produce clinically validated assays for real-time detection of the novel coronavirus.
•The patient clinical material that HPA has does not react with the specific detection assays which we have for OC23 [OC43? - alert], 229E, NL63 or SARS.
•The whole genome of the material that is described in ProMed post#501 is expected to be published by Professor Ron Fouchier, Rotterdam, in the next 24-48 hours. This sequence will be based on cultured virus which has been in Rotterdam since early July.
•The sequence data that HPA has from the London case is based on direct detection in clinical material obtained at the weekend. The HPA does not yet have a virus isolate, although obviously clinical material is already in tissue culture in an attempt to make isolates from the London case.
•HPA welcomes offers of reagents or information from scientists working in this area which may be useful in this situation.
References:
Emery et al. Real-time reverse transcription-polymerase chain reaction assay for SARS-associated coronavirus. Emerg Infect Dis. 2004 Feb;10(2):311-6.
Vijgen et al. A pancoronavirus RT-PCR assay for detection of all known coronaviruses. Methods Mol Biol. 2008;454:3-12.

Comment